wherein the immunogenic protein-based carrier is derived from a protein selected from the group consisting of malaria T-cell epitope, an outer membrane protein of Neisseria Meningitidis, cationized bovine serum albumin, Keyhole Limpet Hemocyanin, polylysine and human serum albumin; and

wherein in the conjugate the ganglioside derivative is covalently bound to the immunogenic protein-based carrier by a stable amine bond between the C-4 carbon of the altered sphingosine base of the altered ceramide portion of the ganglioside derivative and the nitrogen of an ε-aminolysyl group of the immunogenic protein-based carrier, so as to stimulate or enhance production of an antibody to GD2, GD3 and GT3 in the subject, whichever ganglioside is present as a derivative in the conjugate, and thereby delay recurrence of melanoma in said subject at risk of relapse of said melanoma.--

REMARKS

Claims 109-122 are pending in the application. These claims have all been cancelled without disclaimer or prejudice to applicants' right to pursue patent protection for the subject matter thereof in a subsequent application. New claims 123-146 are submitted herewith for the Examiner's review and consideration. These claims are completely supported by the application as filed (see below) and thus they raise no issue of new matter. Therefore, entry of this Amendment into the file of the application is respectfully requested such that claims 123-146 will be pending.

In particular, support for the new claims 123-146 may be found, inter alia, in the specification as follows: claim 123: page 5,

lines 4-7, page 11, lines 13-24, page 12, lines 23-26 and 30-31, page 19, lines 8-13, page 28, page 29, lines 8-30, page 32, lines 1-20, page 65, lines 9-15, page 75, lines 28-32, page 76, lines 13-21 and Figure 1; claim 124: page 12, lines 15-16; claims 125-128: page 13, lines 8-26; claims 129-131: page 14, lines 1-5; claim 132: see support for claims 123-131 above; claim 133: pages 77-78 and the Experimental Results; claim 134: page 5, lines 4-7, page 11, lines 13-15, page 12, lines 23-26 and 30-31, page 15, lines 11-22, page 19, lines 8-13, page 28, page 29, lines 8-30, page 32, lines 1-20, page 65, lines 9-15, page 75, lines 28-32, page 76, lines 13-21 and Figure 1; claim 135: page 5, lines 4-7, page 11, lines 13-15, page 12, lines 23-26 and 30-31, page 15, line 26 to page 16, line 20, page 19, lines 8-13, page 28, page 29, lines 8-30, page 32, lines 1-20, page 65, lines 9-15, page 75, lines 28-32, page 76, lines 13-21 and Figure 1; claims 136-138: page 17, lines 5-10; claims 139-140: page 18, lines 5-10: claims 141-142: page 55, lines 10-14; claim 143; page 93, lines 1-3; claim 144: page 54, lines 19-21, page 66, lines 4-14 and page 87, lines 27-30; claim 145: page 54, lines 19-21; and claim 146: page 5, lines 4-7, page 11, lines 13-24, page 12, lines 23-26 and 30-31, page 19, lines 8-13, page 28, page 29, lines 8-30, page 32, lines 1-20, page 65, lines 9-15, page 75, lines 28-32, page 76, lines 13-18, pages 77-78, the Experimental Results and Figure 1.

Obviousness-Type Double Patenting Rejection

The Examiner has provisionally rejected claims 109-122 as being unpatentable due to obvious-type double patenting over claims 78, 80-92, 94 and 96-99 of copending Application No. 08/477,097 for reasons already made of record. The Examiner stated in ¶4 on p. 2 of the Office Action that although the conflicting claims are not

identical, they are not patentably distinct from each other because they all claim conjugates and methods of using said conjugates, where the conjugate comprises a ganglioside conjugated to a protein through the ceramide potion. The Examiner stated that thus, the particular species drawn to GM2 or GD2 claimed in the copending application would anticipate the instant genus composition claims.

The Examiner further stated that applicants argue that the provisional rejection should be allowed to drop and that the instant claims be allowed to issue, pursuant to MPEP section 804. In response, however, the Examiner stated that since the instant claims are not allowable, the provisional double patenting rejection is maintained for the reasons of record.

The Examiner has also provisionally rejected claims 109-122 as being unpatentable due to obvious-type double patenting over claims 78-93 and 95-100 of copending Application No. 08/475,784 for reasons already made of record. The Examiner stated in ¶5 on p. 3 of the Office Action that although the conflicting claims are not identical, they are not patentably distinct from each other because they all claim conjugates where the conjugate comprises a ganglioside conjugated to a protein through the ceramide portion. The Examiner stated that thus, the particular species claimed in the copending application would anticipate the instant genus composition claims.

The Examiner further stated that Applicants argue that the provisional rejection should be allowed to drop and that the instant claims be allowed to issue, pursuant to MPEP section 804. In response, however, the Examiner stated that since the instant

claims are not allowable, the provisional double patenting rejection is maintained for the reasons of record.

The Examiner has additionally provisionally rejected claims 109-122 as unpatentable due to obviousness-type double patenting over claims 97, 101-111 and 113-118 of copending Application No. 08/196,154 for reasons already made of record. The Examiner stated in ¶6 on p. 3 of the Office Action that although the conflicting claims are not identical, they are not patentably distinct from each other because they claim conjugates, and methods of using said conjugates, where the conjugate comprises a ganglioside conjugated to a protein through the ceramide portion. The Examiner stated that thus, the GM2 species claimed in the copending application would anticipate the instant genus composition claims.

The Examiner further stated that Applicants argue that the provisional rejection should be allowed to drop and the instant claims be allowed to issue, pursuant to MPEP section 804. In response, however, the Examiner stated that since the instant claims are not allowable, the provisional double patenting rejection is maintained for the reasons of record.

The provisional double-patenting rejections of claims 109-122 of the present application over application Serial Nos. 08/477,097; 08/475,784 and 08/196,154 are respectfully traversed. In response to these rejections, applicants submit that M.P.E.P. §804 IB, in discussing provisional double-patenting rejections between copending applications, requires that the:

> 'provisional' double patenting rejection should continue
> to be made by the examiner in each application as long
> as there are conflicting claims in more than one application

> unless that 'provisional' double patenting rejection is the
> only rejection remaining in one of the applications. If the
> 'provisional' double patenting rejection in one application
> is the only rejection remaining in the application, the
> examiner should then withdraw that rejection and permit the
> application to issue as a patent, thereby converting the
> 'provisional' double patenting rejection in the other
> application into a double patenting rejection at the time one
> application issues as a patent. (emphasis supplied by
> applicants).

Applicants submit, therefore, for the reasons discussed below, that new claims 123-146 are believed to distinguish the invention over all of the references cited by the Examiner to reject claims 109-122, which rejections should therefore be withdrawn. Following such withdrawal, the only remaining rejection in this application would be the provisional double patenting rejection of the claims. In accordance with the M.P.E.P. section quoted above, the provisional double patenting rejection should thus be withdrawn to permit the application to issue as a patent. Such action is therefore respectfully solicited.

Claim Rejections Withdrawn

Applicants note with appreciation the Examiner's statement in ¶9 on p.4 of the Office Action, that the rejections of claims 78-92, 94 and 96-99 under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention, is withdrawn in view of the amendment.

Applicants additionally wish to express their appreciation for the

Examiner's statement in ¶8 on p. 4 of the Office Action that the rejection of claims 78-92, 94 and 96-99 under U.S.C. 103(a) as being unpatentable over Livingston et al. (Cancer Research, 149:7045-7050, 1989), in view of Ritter et al. (Seminars in Cancer Biology, 2:401-409, 1991), Liane et al. (Journal of Biological Chemistry, 249(14):4460-4466, 1974), Livingston et al. (U.S. Patent No. 5,102,663), Ritter et al. (Immunobiol, 182:32-43, 1990), Kensil et al. (The Journal of Immunology, 146(2):431-437, 1991), Marciani et al. (Vaccine, 9:89-96, 1991) and Uemura et al. (J. Biochem, 79(6):1253-1261, 1976) is withdrawn in view of the amendment.

New Grounds of Rejection

The following new ground of rejection is set forth by the Examiner in the Office Action.

In ¶9 of the Office Action, the Examiner stated that claims 109-122 are rejected under 35 U.S.C. 103(a) as unpatentable over Wiegand et al. U.S. Patent No. 5,599,914 issued Feb. 4, 1997, filed Nov. 24, 1989 ("Wiegand") in view of Fiume et al., Critical Rev. Therapeutic Drug Carrier Systems, 4(4):265-284, 1998 ("Fiume"), Ritter et al., Seminars in Cancer Biology, 2:401-409, 1991 ("Ritter"), Kensil et al., The Journal of Immunology, 146(2):431-437, 1991 ("Kensil"), Marciani et al., Vaccine, 9:89-96, 1991 ("Marciani") and Uemura et al., J. Biochem, 79(6):1253-1261, 1976 ("Uemura").

With regard to the above-described rejection the Examiner stated that Wiegand discloses modified glycosphingolipids (GM3, GD3, GM2 and GM1). The Examiner stated that Wiegand discloses a method for chemical modification of the sphingoid portions of glycosphingolipids to make glycosphingolipids capable of coupling

to proteins (citing to the abstract of the reference). The Examiner
stated that Wiegand discloses that the method of chemical
modification is that of ozonolysis at the C-4 double-bond of the
sphingosine base resulting in the formation of a reactive aldehyde
species (citing to col. 2, line 43 - col.3, line 67). The Examiner
stated that Wiegand discloses that the aldehyde group is
susceptible to reductive amination. The Examiner further stated,
however, that Wiegand fails to disclose conjugation of the modified
glycosphingolipid to KLH via an amine linkage between the C-4
carbon of sphingosine base and an ε-aminolysyl group of KLH. The
Examiner additionally stated that Wiegand also fails to disclose a
composition that comprises a saponin derivable from the bark of the
Quillaja saponaria Molina Tree (QS-21).

The Examiner stated that Fiume (1998) teaches that reductive
amination of reactive aldehyde species with proteins having ε-
lysine groups is well known in the art (citing to pages 268-269).
The Examiner stated that specifically, Fiume teaches that an
aldehyde group of a galactosyl residue may be reacted with an ε-
lysine of a protein.

The Examiner stated that Ritter (1991) teaches that IgG responses
to gangliosides may be increased by the covalent attachment of
foreign carrier proteins such as KLH to the gangliosides resulting
in the T cell help necessary for the response (citing to page 406,
paragraph 1). The Examiner stated that Ritter teaches that the
advantage of inducing an IgG antibody response (versus IgM) against
gangliosides is that IgG: a) has a high affinity, b) is better able
to penetrate solid tissues, c) is able to mediate antibody-
dependent cell-mediated cytotoxicity, and d) is generally

detectable in the serum for longer periods after immunization.

The Examiner stated that Kensil et al. teach that QS-21 (i.e., the instant carbohydrate derivable from the bark of a Quillaja saponaria Moline tree) produced a higher antibody response than conventional aluminum hydroxide (citing to page 433, column 2, paragraph 4, and Figure 3). The Examiner stated that Kensil et al. also teach that the immune responses obtained with QS-21 reached a plateau at doses between 10-80 ug in mice (citing to page 433, column 1, paragraph 3).

The Examiner stated that Marciani et al. teach the use of QS-21 adjuvant was useful because it did not cause a toxic reaction in cats (citing to page 93, paragraph 1).

The Examiner stated that Uemura et al. teach that the ozonolysis and reduction of various sphingolipids did not affect the haptenic reactivity of the ganglioside derivative with antibodies.

The Examiner thus stated that it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to have used the modified glycosphingolipids of Wiegand to make glycoconjugates that are the same as those claimed. The Examiner stated that Wiegand teaches a modified glycosphingolipid that has a reactive aldehyde group (at the C-4 position of the sphingosine base) that may be used for coupling to proteins as taught by Fiume, because Fiume demonstrates that methods of reductive amination to link proteins, via ε-lysine residues, to reactive aldehyde groups is known in the art. The Examiner stated that because Wiegand teaches a method of ozonolysis

that results in the formation of a reactive aldehyde species, the bond that would be formed between the C-4 carbon of the sphingosine base and the KLH would be an amino linkage that would cause the C-4 carbon to be present in a CH_2 group. The Examiner stated that it would have been *prima facie* obvious to one of ordinary skill in the art to have used KLH as the protein carrier because, as Ritter teaches, attachment of gangliosides to carrier proteins such as KLH increases IgG responses to gangliosides. The Examiner also stated that it would have been *prima facie* obvious to one of ordinary skill in the art to add S-21, because, as taught by Kensil, it provides for a higher antibody response, and QS-21 provides the advantage that it is not toxic to animals (citing to the Marciani reference).

The Examiner stated that it would have been *prima facie* obvious to one of ordinary skill in the art to optimize the doses of QS-21 in the composition, and that it would also have been *prima facie* obvious to one of ordinary skill in the art to optimize the weight ratio of the components of the composition to provide an optimal response.

The Examiner additionally stated that one would have reasonably expected the conjugation procedure to work as substituted because conjugation through the ε-aminolysyl groups of carrier proteins for enhancing immunogenicity is routine in the art, and as Uemura (1976) teaches, ozonolysis and reduction of various sphingolipids does not affect the haptenic reactivity with antibodies.

Applicants respectfully traverse this new ground of rejection. The invention recited in new claims 123-146 submitted herewith is not

suggested to one of ordinary skill in this field of art by the disclosure of the above-cited references, whether they are taken alone or in combination, for the reasons set forth below.

Turning first to Wiegand, the subject reference is directed to the chemical modification of the sphingoid portions of glycosphingolipids and the subsequent coupling of such modified glycosphingolipids to other molecules, such as proteins. The glycosphingolipids useful in the process disclosed by the reference, however, are disclosed in a generic fashion, with no teaching or suggestion that any particular species within this genus would perform more effectively than any other, i.e., when linked to form an immunoconjugate composition such as is taught and claimed in the present application. This broad scope of disclosure is specifically demonstrated in, for example, Example B of the reference (commencing at column 5), which describes, inter alia, the preparation and subsequent coupling of reductively aminated ozonolysis products of the gangliosides GM3, GD3, GM2 and GM1. No particular ganglioside is described as being preferred or as performing any more effectively than any of the other gangliosides falling within the scope of the reference. In particular, there is no teaching or suggestion that the modification and conjugation of, specifically, any of the GD2, GD3 lactone, O-acetyl GD3 and GT3 gangliosides (as specifically recited in applicants' new independent claims) would produce a composition having properties superior in any fashion to those obtained with the use of any other(s) of the gangliosides falling within the scope of the genus of glycosphingolipids disclosed in the reference.

Several additional features which further distinguish the reference

from the Wiegand reference are pointed out by the Examiner herself in the Office Action. In particular the Examiner stated (as noted above) on p. 5 of the Office Action that: (i) Wiegand fails to disclose conjugation of the modified glycosphingolipid to KLH, (ii) Wiegand fails to disclose conjugation via an amine linkage between the C-4 carbon of sphingosine base and an ε-aminolysyl group of KLH, and (iii) Wiegand also fails to disclose a composition that comprises a saponin derivable from the bark of a Quillaja saponaria Molina tree (i.e., QS-21).

The presently claimed invention is thus distinguishable and therefore patentable over Wiegand on several grounds, as summarized below. First, the Wiegand reference contains no teaching or disclosure which would suggest to one of ordinary skill in this art to use, in particular, the GD2, GD3 lactone, O-acetyl GD3 and GT3 ganglioside derivatives specifically recited in applicants' claims, in an immunoconjugate of the present invention. Second, there is no teaching or disclosure in the Wiegand reference which teaches or suggests the conjugation of a (modified) glycosphingolipid with any of the immunogenic protein-based carriers recited in applicants' independent claims <u>other</u> than human serum albumin. That is, the only particular example of such a protein disclosed in Wiegand is human serum albumin ("HSA") at, for example, column 5, lines 25-30. Third, there is no disclosure in Wiegand which would suggest the formation of a conjugate+QS-21 incorporating a ganglioside derivative selected from the group consisting of GD2, GD3 lactone, O-acetyl GD3 and GT3. As noted above, the Office Action states (see p. 5) that Wiegand fails to disclose a composition that comprises a saponin derivable from the bark of a Quillaja saponaria Molina tree, i.e., QS-21. Fourth, it is not obvious from the disclosure of

the reference that a vaccine comprised of a conjugate of a ganglioside derivative selected from GD2, GD3 lactone, O-acetyl GD3 and GT3 coupled to an immunogenic protein-based carrier such as, for example, Keyhole Limpet Hemocyanin, and a saponin derivable from the bark of a Quillaja saponaria Molina tree would provide a superior immunogenic effect in human cancer patients.

More particularly, with regard to the issue whether it would be obvious to one of ordinary skill in the art to couple a GD2, GD3 lactone, O-acetyl GD3 or a GT3 ganglioside derivative to an immunogenic protein based carrier such as, e.g., Keyhole Limpet Hemocyanin, (i.e., one of several immunogenic protein-based carriers recited in applicants' claims) the Examiner as noted above stated in the Office Action that Wiegand does not teach or suggest such a construct. The Examiner thus has cited the Ritter reference in an effort to supply this missing element. There is, however, no teaching in either the Wiegand reference or the Ritter reference to suggest the combination of their disclosures. The references, moreover, teach away from such a combination in that Wiegand discloses the conjugation of a modified glycosphingolipid to (only) human serum albumin, see, e.g., Example B at col. 5, lines 24-28 whereas, in contrast, the new independent claims to the present invention recite that the immunogenic protein-based carrier may additionally (i.e., in addition to human serum albumin) be chosen from among malaria T-cell epitope, an outer membrane protein of Neisseria Meningitidis, cationized bovine serum albumin, Keyhole Limpet Hemocyanin and polylysine, none of which are disclosed in the reference. There is thus no support for the Examiner's proposed combination of Wiegand and Ritter.

Further to the above, there is also no disclosure contained in the remaining cited references to suggest to one of ordinary skill in this art the formation of a GD2 (or GD3 lactone, O-acetyl GD3 or GT3)-[e.g.]KLH (or malaria T-cell epitope, etc.) conjugate in combination with QS-21. The Examine acknowledged in the Office Action (see p. 5) that Wiegand fails to disclose a composition comprising a saponin derivable from the bark of a Quillaja saponaria Molina tree. Ritter also contains no such disclosure. The Examiner thus cited the Kensil and Marciani references for their disclosure (noted above) concerning QS-21. Neither of these references, however, discloses the conjugation of the modified ganglioside derivatives recited in applicants' new claims with an immunogenic protein-based carrier such as, e.g., Keyhole Limpet Hemocyanin. Moreover, as demonstrated by the Experimental Results described in the present application, the inclusion of the QS-21 adjuvant in the claimed composition provides unexpectedly improved results over those obtained with the use of other known adjuvants. Applicants submit, therefore, that these improved results evidence that the inclusion of the QS-21 adjuvant in a composition comprising the GD2 (or GD3 lactone, O-acetyl GD3 or GT3) ganglioside-[e.g.]KLH conjugate would not be obvious to one of ordinary skill in this art.

In summary, therefore, as recognized by the Examiner in her Office Action and as further established by the arguments provided herein, the combination of Wiegand with any or all of the Ritter, Kensil and Marciani references neither teaches nor suggests the formation of a conjugate in accordance with new claims 123-146, in combination with QS-21, linked via the specific mode of linking the conjugate together as also recited in the subject claims. For this

reason, the invention as presently claimed is believed to patentably distinguish over the cited references.

Moreover, the Experimental Results portion of applicants' specification conclusively demonstrates that compositions similar to those of the present invention are very successful in stimulating or enhancing the production of antibodies in human subjects so as to treat and/or prevent cancers, particularly melanoma, in such human subjects. Such a result could not have been predicted from the cited art. Applicants attach hereto as **Exhibit A** a copy of a paper by Ragupathi, et al., "Induction of Antibodies Against GD3 Ganglioside In Melanoma Patients By Vaccination With GD3-Lactone-KLH Conjugate Plus Immunological Adjuvant QS-21", <u>Int. J. Cancer</u>:85 659-666 (2000). Exhibit A clearly demonstrates that compositions based on the <u>GD3 ganglioside</u>-KLH+QS-21 are **NOT** effective in stimulating the production of GD3 antibodies in humans. In particular, the authors stated, at p. 665, second column, ¶2, lines 18-19, that "GD3-KLH <u>failed to induce antibody against GD3</u>". (emphasis supplied by applicants). Applicants submit, therefore, that the improved results with the conjugates similar to those of the present invention + QS-21, in contrast to the poor results achieved with a comparable GD3-KLH conjugate + QS-21 as described by the authors of the subject exhibit, provide convincing evidence that the presently claimed invention would **NOT** be obvious to one of ordinary skill in this art over the cited references, whether such references are taken alone or in any combination.

Applicants therefore submit that for the preceding reasons, the invention as presently claimed is distinguishable over the Wiegand, Ritter, Kensil and Marciani references cited in combination to

reject claims 109-122. Whether the references are taken individually or in combination, the arguments above clearly support applicants' position that the invention as presently claimed is not obvious over the disclosure of the cited prior art [1,2] Moreover, as discussed in the footnotes below, neither the Fiume nor the Uemura references, cited by the Examiner in combination with the Wiegand, Ritter, Kensil and Marciani references to reject claims 109-122, supply the elements missing from the above-discussed references in a manner so as to render the invention as now claimed obvious to one of ordinary skill in this art. The Examiner is thus respectfully requested to reconsider and withdraw her rejection of claims 109-122 based on the references discussed above.

---

1 The Fiume reference cited by the Examiner in combination with the other references discussed above to reject the claims relates to the placement of an aldehyde derivative on the sugar portion of a sphingolipid and linking this structure to an ε-amino group of a lysine located upon a protein. The Examiner's suggestion on p.5 of the Office Action that Fiume has a more generic teaching, i.e., that it teaches that reductive amination of the reactive proteins having ε-lysine groups is well known in the art is <u>not</u> supported by the disclosure of the reference, which is limited to the chemistry of sugar-based compositions. Moreover, as shown, for example, in the paper by Ritter et al. attached hereto as **Exhibit B**, entitled ''Antibody Response to Immunization With Purified GD3 Ganglioside and GD3 Derivatives (Lactone, Amide and Gangliosidol) in the Mouse'', Immunobiol.:, 32-43 (1990) it was well known in the art that at least as of the date of the reference the conjugation of ganglioside derivatives through the sugar portion did not provide an composition effective for stimulating or enhancing the production of antibodies (see, e.g., Table 1 on p.34).

2 Further according to the Examiner (at p. 6 of the Office Action) the Uemura reference additionally cited in combination with the other above-discussed references to reject the claims teaches that the ozonolysis and reduction of various sphingolipids did not affect the haptenic activity of the ganglioside derivative with antibodies. The Ragupathi et al. reference attached as **Exhibit A**, however, demonstrates that the Examiner's statement is not generally correct since the GD3-based conjugate, formed with ozonolysis and reduction of the sphingolipid, ''[f]ailed to induce antibody against GD3'' (see p. 665), thus demonstrating that haptenic activity of certain sphingolipids can be negatively affected by such ozonolysis and reduction.

Applicants   :   Philip Livingston and Friedhelm Helling
U.S. Serial No.:   08/477,147
Filed   :   June 7, 1995
Page 25

Summary

For the reasons set forth hereinabove, applicants respectfully request that the Examiner reconsider and withdraw the various grounds of objection and rejection set forth in the Office Action and earnestly solicit allowance of the now pending claims, i.e., nos. 123-146.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' attorneys invite the Examiner to telephone either of them at the number provided below.

A fee of $42.00 is believed to be due for the addition of an additional independent claim and thus a check for that amount is enclosed herewith. If any additional fees are required, authorization is hereby given to charge the amount of the required fee to Deposit Account No. 03-3125.

                                        Respectfully submitted,

John P. White
Registration No. 28,678
Mark A. Farley
Registration No. 33,170
Attorneys for Applicant(s)
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

Publication of the International Union Against Cancer

INDUCTION OF ANTIBODIES AGAINST GD3 GANGLIOSIDE IN MELANOMA PATIENTS BY VACCINATION WITH GD3-LACTONE-KLH CONJUGATE PLUS IMMUNOLOGICAL ADJUVANT QS-21

Govindaswami Ragupathi[1,2*], Michael Meyers[2], Sucharita Adluri[1], Lisa Howard[1], Cristina Musselli[1] and Philip O. Livingston[1,2]

[1]*Laboratory of Tumor Vaccinology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA*
[2]*Clinic Immunology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA*

The gangliosides GD3, GD2 and GM2 are expressed on the cell surface of malignant melanomas, GD3 being the most abundant. We have shown that immunization of melanoma patients with GM2 adherent to Bacillus Calmette-Guerin (GM2/BCG) induced an IgM antibody response. Vaccines containing GM2-keyhole limpet hemocyanin (KLH) conjugate and the immunological adjuvant QS-21 induced a higher titer IgM response and consistent IgG antibodies. Patients with antibodies against GM2 survived longer than patients without antibody. On the other hand, our previous trials with GD3/BCG, GD3 derivatives including GD3-lactone (GD3-L)/BCG failed to induce antibodies against GD3. In our continuing efforts to induce antibody against GD3, we have immunized groups of 6 melanoma patients with GD3-KLH or GD3-L-KLH conjugates containing 30 μg of ganglioside plus 100 μg of QS-21 at 0, 1, 2, 3, 7 and 19 weeks. Prior to vaccination, no serological reactivity against GD3 or GD3-L was detected. After immunization, IgM and IgG antibodies were detected against both GD3 and GD3-L in the GD3-L group exclusively. The GD3-L-KLH vaccine induced IgM titers against GD3-L of 1:40–1/1,280 in all patients and IgG titers of 1/160–1/1,280 in 4 patients. These antibodies also strongly cross-reacted with GD3. ELISA reactivity was confirmed by immune thin-layer chromatography on GD3 and melanoma extracts. Sera obtained from 4 of these 6 patients showed cell surface reactivity by FACS and from 2 showed strong cell surface reactivity by immune adherence (IA) assay and complement lysis against the GD3 positive cell line SK-Mel-28. *Int. J. Cancer* 85: 659–666, 2000.
© 2000 Wiley-Liss, Inc.

Gangliosides are sialic acid containing glycosphingolipids composed of a carbohydrate moiety attached to ceramide. Gangliosides GM2, GD2 and GD3 are expressed on the cell surface of human malignant melanomas and other tumors of neuroectodermal origin. These antigens have been demonstrated to be susceptible targets for treatment with monoclonal antibodies (MAbs) and vaccines (Jurcic *et al.*, 1997; Livingston, 1995; Ragupathi, 1996; Scheinberg and Chapman, 1995). We and others have shown that the presence of antibodies against GM2 (either naturally or vaccine-induced) has been associated with an unexpectedly favorable disease-free and overall survival. We demonstrated that the optimal way to immunize against GM2 is by vaccinating with GM2 covalently conjugated to keyhole limpet hemocyanin (GM2-KLH) plus immunological adjuvant QS-21 (Helling *et al.*, 1995). However, GD3 is the dominant melanoma ganglioside and we have been unable to induce antibodies against GD3 in melanoma patients by active immunization with GD3-expressing melanoma cells or purified GD3 or GD3 congeners such as GD3-lactone plus Bacillus Calmette-Guerin (GD3-L/BCG) (Ritter *et al.*, 1991). However, GM3-L has been reported to be a more effective immunogen than GM3 (Nores *et al.*, 1987), presumably due to the increased molecular rigidity resulting from lactone ring formation, and the KLH conjugate vaccine is more immunogenic than the previous BCG vaccine. Consequently, we have tested the immunogenicity in melanoma patients of GD3-KLH plus QS-21 and GD3-L-KLH plus QS-21 vaccines and report the successful induction of antibodies against purified GD3 and melanoma cells expressing GD3 in the majority of patients.

MATERIAL AND METHODS

Material

GD3 extracted from bovine buttermilk was received from Matreya (Pleasant Gap, PA). GM1, GM2, GM3 and GD2 extracted from bovine brain, BSA, sodium cyanoborohydride, 4-chloro-1-naphtol and *p*-nitrophenyl phosphate were purchased from Sigma (St. Louis, MO). QS-21 (Kensil *et al.*, 1991) was obtained from Aquila (Framingham, MA). Clinical grade KLH was obtained from PerImmune (Rockville, MD). Goat anti-human IgG and IgM conjugated with alkaline phosphatase obtained from Kierkegaard and Perry (Gaithersburg, MD) were used for ELISA. Goat anti-human IgM or IgG labeled with fluorescein isothiocyanate (FITC) were obtained from Southern Biotechnology Associates (Birmingham, AL) and used in a fluorescence-activated cell sorter (FACS). Horseradish peroxidase-conjugated goat anti-human IgM and IgG purchased from TAGO (Burlingame, CA) was used for dot-blot immune staining and immune thin-layer chromatography (ITLC). Rabbit anti-mouse immunoglobulins conjugated with horseradish peroxidase were obtained from Zymed (San Francisco, CA) and used for ITLC with mouse control MAb R24 against GD3 (Pukel *et al.*, 1982). High performance thin-layer chromatography (HPTLC) silica gel plates were obtained from Merck (Darmstadt, Germany).

Vaccine preparation

GD3-KLH conjugate was prepared as described previously (Fig. 1a) (Helling *et al.*, 1994). The principle involved in the conjugation procedure is cleavage of the double bond of ceramide by ozone, generation of an aldehyde group and conjugation to ε-amino groups on lysine of KLH by reductive amination. The GD3-KLH conjugate was prepared in 3 batches. The amount used for conjugation, the percent recovery and the GD3/KLH epitope ratio for the GD3-L-KLH vaccine are summarized in Table I. More than 23% of GD3 in the reaction mixture was conjugated with KLH. The GD3/KLH epitope ratio for the combined preparation was 1,049.

GD3-L-KLH vaccine. Because of the unstable nature of GD3-L, we firstly prepared the GD3-KLH conjugate then converted it to GD3-L-KLH by acid treatment (Fig. 1b) and lyophilized immediately. Briefly, equal volumes of GD3-KLH and glacial acetic acid (v/v) were mixed in a sterile glass tube. To monitor GD3-L conversion, the conversion of free GD3, a small portion of which had not been removed completely from the conjugation reaction, was determined by TLC. After 4 hr at 37°C with gentle shaking, when about

RAGUPATHI ET AL.

Figure 1 – (a) Synthesis of GD3-KLH conjugate after ozone cleavage and reductive amination. (b) Conversion of GD3-KLH conjugate to GD3-L-KLH conjugate.

Batch number[1]	Amount used for conjugation (mg)		Ratio by weight GD3:KLH	The amount of GD3 and KLH in conjugate (mg)		Recovered (%)		Epitope ratio of conjugate GD3/KLH
	GD3	KLH		GD3	KLH	GD3	KLH	
1	5.0	7.5	1:1.5	0.90	5.04	18.0	67.2	1,076.0
2	3.0	5.0	1:1.6	0.78	4.08	26.0	81.6	1,118.2
3	5.0	6.0	1:1.2	0.99	6.00	19.8	100	952.5
Combined	13.0	18.5	1:1.4	2.67	15.12	20.5	81.7	1,048.9

[1] All 3 batches were combined to prepare GD3-KLH and GD3-L-KLH conjugate vaccine (see Material and Methods).

80% of the GD3 had been lactonized, the acetic acid was quickly removed using a Centriprep (Amicon, Beverly, MA; 30 kDa molecular cut-off filter) with multiple saline washes. The conjugate was sterilized by passing through a 0.22-μm filter. The amount of GD3 or GD3-L in the conjugate was determined by estimating the sialic acid content by the resorcinol method (Svennerholm, 1963). GD3-KLH or GD3-L-KLH conjugate containing 30 μg ganglioside was aliquoted to individual vials and lyophilized under sterile conditions. In both cases, prior to the injection, 100 μg of QS-21 were mixed with the vaccine as it was reconstituted in normal saline solution.

Patients and clinical protocol

Patients with AJCC stage III or IV metastatic malignant melanoma (regional or systematic metastases) who were free of detectable melanoma within 2 weeks to 6 months after surgery were candidates for this trial. No patient had received prior chemotherapy. GD3-KLH or GD3-L-KLH conjugate containing 30 μg of ganglioside and 100 μg immunological adjuvant QS-21 were mixed immediately prior to vaccine administration in a total volume of 1 ml saline. Four vaccinations were administered s.c. at 1-week intervals, 2 additional vaccinations were administered at

TABLE II – PEAK ANTIBODY RESPONSE OF PATIENTS AFTER VACCINATION WITH GD3-KLH OR WITH GD3-L-KLH AS DETERMINED BY ELISA

Patient	Peak reciprocal ELISA titer							
	GD3				GD3-L			
	IgM		IgG		IgM		IgG	
	Pre	Post	Pre	Post	Pre	Post	Pre	Post
GD3-KLH lyophilized								
1	0	0	0	0	NT[1]	NT	NT	NT
2	0	0	0	0	NT	NT	NT	NT
3	20	80	0	80	NT	NT	NT	NT
4	0	0	0	0	NT	NT	NT	NT
5	0	0	0	0	NT	NT	NT	NT
6	0	20	0	20	NT	NT	NT	NT
GD3-L-KLH lyophilized								
1	0	40	0	160	0	40	0	160
2	0	0	0	0	0	40	0	0
3	0	40	0	20	0	160	0	0
4	0	160	10	1,280	0	640	0	1,280
5	0	40	0	160	0	40	0	1,280
6	0	1,280	0	320	0	1,280	0	1,280

[1]Not tested, because of the absence of antibodies against GD3 antibody.

intervals of 7 and 19 weeks from the date of first vaccination, under an MSKCC IRB approved protocol. Peripheral blood (20–30 ml) was drawn immediately before each vaccination, and 2 weeks after the 4th, 5th and 6th vaccinations.

ELISA

ELISAs were performed as described previously (Helling et al., 1995). To determine the titers of GD3 and GD3-L antibodies, ELISA plates were coated with GD3-L or GD3 at 0.1 μg per well in ethanol. Serially diluted patient serum was added to wells of the coated plate and incubated for 1 hr at room temperature. Rabbit anti-human IgM or IgG conjugated with alkaline phosphatase served as second antibodies. The antibody titer was defined as the highest serum dilution showing an absorbance 0.1 or greater over that of normal sera. Immune sera were also tested for non-specific "stickiness" on plates that were processed identically but without ganglioside, and reading was subtracted from the value obtained in the presence of gangliosides.

Immune thin layer chromatography (ITLC)

Immune staining of gangliosides with MAbs or human sera was performed after separation of purified gangliosides or melanoma extracts on HPTLC silica gel glass plates as described previously (Hamilton et al., 1993). The plates were coated with 1% Plexigum (Polyscience, Warrington, PA) in n-hexane, blocked with 3% BSA in PBS for 2 hr and incubated with patient sera (diluted 1:150 in PBS) overnight at room temperature. The plates were washed with PBS containing 0.05% Tween 20 (Fisher Scientific, Fair Lawn, NJ) and incubated with anti-human IgG or IgM antibodies conjugated with horseradish peroxidase at 1:200 dilution for 3 hr at room temperature. The plates were then washed with PBS-0.05% Tween 20 and developed with 4-chloro-1-naphtol-H_2O_2.

Dot-blot immune stain

Gangliosides GD3, GD3-L, GD2, GM1, GM2, GM3 and fucosyl (Fuc)-GM1 (0.1 μg) were spotted on nitrocellulose strips. The unreacted sites were blocked with 3% HSA-0.05% Tween-20 in PBS. The strips were treated as described for ITLC except coating with Plexigum. The intensity of spots in dot-blot immune stains was graded -, +, ++ or +++.

Fluorescence activated cell sorter (FACS) assay

The GD3 positive melanoma cell line SK-MEL-28 served as a target. Single cell suspensions of 2×10^5 cells per tube were washed with 3% FCS in PBS and incubated with 20 μl of 1:20 diluted antisera or MAb R24 for 30 min on ice. After washing the

cells twice with 3% FCS in PBS, 20 μl of 1:15 rabbit anti-human IgG or IgM-labeled with FITC were added. The suspension was mixed, incubated for 30 min and washed. The percent positive population and mean fluorescence intensity of stained cells were analyzed using a FACS Scan (Becton-Dickinson, Mountain View, CA) (Zhang et al., 1995).

Immune adherence (IA) assay

The IA assay measures rosetting of human RBC (blood group O) with guinea pig complement on target cells (SK-MEL-28) mediated by complement binding antibodies, and was performed as described previously (Shiku et al., 1976). Individual target cells were scored as positive when 50% or more of the cell perimeter was surrounded by indicator cells.

Complement-dependent cytotoxicity (CDC)

CDC was assayed at a serum dilution of 1:10 with SK-MEL-28 cells and human complement by a chromium-release assay as previously described (Helling et al., 1995). All assays were carried out in triplicate. Cells incubated only with culture medium, complement, antisera or MAb R24 served as controls. Spontaneous release was calculated based on the chromium released by target cells incubated with complement alone. Maximum release was determined by incubating target cells with complement and 1% Triton X-100. Percent cytolysis was calculated according to the formula:

Specific release (%)

$$= \frac{\text{experimental release} - \text{spontaneous release}}{\text{maximum release} - \text{spontaneous release}} \times 100$$

Inhibition assay

Antisera at 1:150 dilution or MAb R24 at 1 μg/ml were mixed with various concentrations of structurally related and unrelated ganglioside antigens. The mixture was incubated at room temperature for 30 min and tested on a GD3-coated plate by ELISA. Percentage inhibition was calculated as the difference in absorbance (ELISA) between the uninhibited and inhibited serum.

RESULTS

Clinical considerations

All patients signed informed consent prior to vaccination. Complete blood counts (CBC), liver function tests and clinical evaluations were repeated at 2-month intervals. Toxicity was restricted

662

RAGUPATHI ET AL.

FIGURE 2 – Time course of the induction of IgM (a) and IgG (b) antibodies in 6 patients immunized with GD3-L-KLH plus QS-21.

to grade II local erythema and induration at vaccination sites lasting 3–5 days in all patients and grade I fever and flu-like symptom lasting 1–2 days after 2–3 immunizations in one half of the patients. This is the pattern of side effects associated with QS-21 administration at the 100-µg dose (Livingston et al., 1994). No other side effects were detected.

ELISA responses against GD3 and GD3-L

The ELISA titers against GD3 and GD3-L are summarized in Table II. Before vaccination, IgG antibodies against GD3 or

GD3-L were detected in 1 patient (titer 1/10) and IgM antibodies were detected at a titer of 1/20 in 1 patient. After vaccination, only one patient vaccinated with GD3-KLH developed detectable IgM and IgG antibodies against GD3 (titers 1/80). Consequently, further analysis was not carried out with GD3-KLH sera. The GD3-L-KLH vaccines, however, induced IgM titers against GD3-L of 1/40–1/1,280 in all patients and IgG titers of 1/160–1/1,280 in 4 patients (Table II). These antibodies also strongly cross-reacted with GD3. Peak reciprocal IgM titers of 40–1,280 were seen against GD3 in 5 of 6 patients and peak reciprocal IgG titers

FIGURE 3 – ITLC with GD3, GD3L, GM2, GD2 and melanoma extract and sera from patient vaccinated with GD3-L-KLH. Chimeric MAb R24 was used as a control.

TABLE III – ANTIBODY RESPONSE OF PATIENTS AFTER VACCINATION WITH GD3-L-KLH AS DETERMINED BY DOT-BLOT[1]

Patient number	IgM							IgG						
	GD3-L	GD3	GD2	GM1	GM2	GM3	FGM1	GD3-L	GD3	GD2	GM1	GM2	GM3	PGM1
1 Pre	−	−	−	+	−	−	±							
1 Post	+++	+++	−	+	−	+	+	+++	+++	−	−	−	−	−
2 Pre	−	−	−	+	+	−	++							
2 Post	+++	+++	−	+++	+	+++	−	±	−	−	−	−	−	−
3 Pre	±	−	−	±	−	+	+							
3 Post	+++	+++	−	−	++	−	+	+	+	−	±	++	−	−
4 Pre	−	−	−	−	−	−	+							
4 Post	+++	+++	−	−	−	+	−	+++	++	−	−	−	−	−
5 Pre	−	−	−	−	−	±	−							
5 Post	+++	+++	−	±	−	+++	−	+++	++	−	−	−	−	−
6 Pre	−	−	−	−	−	−	++							
6 Post	+++	+++	+++	−	−	−	++	+++	++	−	−	−	−	−
R24	−	−	−	−	−	−	++	+++	+++	−	−	−	−	−
696	±	−	−	+++	−	−	−	+++	+++	−	−	−	−	−

[1]Dot-blot immune stains were graded: − (negative), + (weakly positive), ++ (positive) and +++ (strongly positive). FGM1, fucosyl GM1; R24 and 696 are MAbs against GD3 and GM2, respectively.

against GD3 were 160–1,280 in 4 of 6 patients. The ELISA time course of IgM and IgG antibody induction against GD3 with all sera in all 6 patients receiving the GD3-L-KLH vaccines is shown in Figure 2. IgM antibody titers remained higher than IgG titers at most time points, including after the 2 booster vaccinations. In general, titers were no higher after the booster vaccinations then after initial vaccinations.

Immune response with other gangliosides by ITLC and dot-blot

Pre- and post-vaccination sera of all 6 patients receiving the GD3-L-KLH vaccine were tested by ITLC for reactivity with GD3-L, GD3, GD2 and GM2 as well as with melanoma extract. The immune reactivities of pre- and post-vaccination sera from patient 4 along with chimeric MAb R24 are shown in Figure 3. Sera from 5 of 6 patients showed IgM antibody reactivity as strong as patient 4 against GD3-L and GD3. Sera from patients 1, 4, 5 and 6 also showed comparable IgG reactivity with

GD3-L and GD3. Most of the IgM antibodies cross-reacted weakly with GM2 and GD2, whereas IgG antibodies showed only weak cross-reactivity with GD2. Both IgM and IgG reactivities were also seen with higher migrating bands in the melanoma extract, GD3-L.

The specificity of ganglioside antibodies detected in patient sera before and after immunization was also determined by dot-blot immune staining on nitrocellulose membranes containing gangliosides GD3-L, GD3, GD2, GM1, GM2, GM3 and Fuc-GM1. The results are summarized in Table III. A strong positive reactivity f 3+ for IgM antibodies against GD3-L and GD3 was seen in the sera of all 6 patients. Reactivity of 3+ for IgG antibodies was seen in 4 patients with GD3-L and GD3. Pre- immunization IgM and IgG antibodies from all patients showed no reactivity with GD3, although some patients had a low pre-immunization IgM antibody level against GM2 and GM1. Reactivity with these gangliosides

664   RAGUPATHI ET AL.

TABLE IV - CELL SURFACE REACTIVITY AGAINST SK-MEL-28 CELLS OF PATIENT SERA AFTER VACCINATION WITH GD3-L-KLH[1]

| Patient | PACS | | | | SK-MEL-28 | | | |
| | IgM | | IgG | | IA | | CDC | |
	Pre	Post	Pre	Post	Pre	Post	Pre	Post
1	9.5	9.7	11.0	35.5	Neg	Neg	4.3	7.0
2	8.9	9.7	10.7	19.8	Neg	Neg	1.5	3.0
3	5.5	13.6	9.9	23.4	Neg	1:5	1.9	2.3
4	10.5	8.7	9.8	95.8	Neg	1:10	1.0	56.0
5	5.0	4.8	2.3	10.5	Neg	Neg	3.4	4.5
6	9.1	80.2	11.5	36.2	Neg	1:40	5.4	51.9

[1]MAb R24 (IgG$_3$) showed 96.75% positive cells by PACS and 26.6% lysis on SK-Mel-21 cells.

was increased after vaccination in 1 patient each against GM1, Fuc-GM1, GM2 and GD2 and in 2 patients against GM3.

Reactivity of antisera with tumor cells

The cell surface reactivity of peak titer post-immunization antibodies was tested on GD3 positive SK-MEL-28 melanoma cells by FACS, IA and CDC assays. The results with sera from patients receiving the GD3-L-KLH vaccine are summarized in Table IV. The percent positive cells by FACS with pre-vaccination sera were low. Sera from patient 6 showed strongly increased IgM reactivity against SK-MEL-28 cells by FACS, and sera from 4 of 6 patients showed IgG reactivity of over 20% after vaccination. Sera from 3 patients showed post-immunization IA reactivity against SK-MEL-28, and sera from 2 patients showed more than 50% CDC against SK-MEL-28. Under similar conditions, specific release with MAb R24 was 26.6%. Post-vaccination sera in the absence of complement and complement without sera were not cytotoxic.

Antibody specificity determined by inhibition

Two different types of inhibition assays were carried out to define further the specificity of GD3 antibodies in immune sera: (1) incubation of sera with GD3, GD2, GM2 or GM1 and testing back against GD3 by ELISA; and (2) incubation of sera with GD3 and testing back against SK-MEL-28 by FACS. A sample experiment demonstrating the inhibition of IgM and IgG ELISA reactivity for patient 6 (who had shown IgM reactivity against GD2 by dot-blot and ITLC) is shown in Figure 4. The results obtained from all 6 patients are summarized in Table V. The results indicate that GD3 inhibited anti-GD3 IgM at least 10-fold more efficiently than GD2, whereas GM2 and GM1 exhibited no inhibition. The anti-GD3 IgG antibodies were specific for GD3 alone; no other ganglioside inhibited GD3 reactivity.

DISCUSSION

Of the melanoma gangliosides considered to be potential targets for immunotherapy, GD3 is the most abundant but also the least immunogenic. Its potential as a target for passive immunotherapy has been documented in patients treated with R24, a murine MAb recognizing GD3. Regression of melanoma metastases after R24 treatment has been demonstrated at several different centers (reviewed by Jurcic et al., 1997; Scheinberg and Chapman, 1995). We have spent considerable effort over the years trying to construct an effective vaccine against GD3 (Livingston, 1995; Ritter et al., 1990b, 1991). Our initial approaches were to vaccinate melanoma patients with melanoma cells, whole cell lysates or with purified ganglioside adsorbed to BCG. Using these methods, we were able to induce antibody against GM2 but not against GD3 (Helling et al., 1995; Livingston et al., 1982; Ritter et al., 1991). These experiences led us to search for ways to improve the poor immunogenicity of GD3. Several reports indicated that chemical modification of gangliosides could augment their immunogenicity. We prepared a series of synthetic ganglioside congeners and adhered them to BCG to induce antibody in laboratory animals and melanoma patients (Ritter et al., 1990a,b, 1991). GD3 amide, GD3

FIGURE 4 - Inhibition of ELISA reactivity of anti-GD3 IgM (a) and IgG (b) antibody with GD3, GD2, GM1 and GM2 gangliosides (patient 6).

gangliosidol, GD3-L I and II and GD3 acetylated at various sites were all more immunogenic than GD3, but the increased antibody titers induced by these synthetic congeners of GD3 were not reactive with unmodified GD3 or melanoma cells (Ritter et al., 1990a,b). Low-titer GD3 reactive autoantibodies have been reported in the serum of some melanoma patients after vaccination with irradiated melanoma cells (Ravindranath et al., 1989), but less frequently and far lower titer than antibodies against GM2 and GD2, and no cell surface reactivity could be demonstrated. However, human MAbs reactive with GD3 have been generated (Yamaguchi et al., 1987). It was clear that GD3 was a poor immunogen in humans, but never the less could be recognized by the human immune system.

Immunization of mice with GM3-L induced antibodies that cross-reacted with unmodified GM3 (Nores et al., 1987) and a

GD3-LACTONE-KLH CONJUGATE VACCINE

665

TABLE V - INHIBITION OF GD3 ANTIBODY ACTIVITY WITH DIFFERENT GANGLIOSIDES[1]

Sera	GD3 target					
	IgM			IgG		
	GD3	GD2	GM2	GD3	GD2	GM2
Patient 1*	3+	2+	2+	NT[2]	NT	NT
Patient 2*	1+	1+	0	NT	NT	NT
Patient 3	1+	0	0	NT	NT	NT
Patient 4	4+	1+	0	NT	NT	NT
Patient 5*	3+	0	0	4+	0	0
Patient 6	4+	2+	0	NT	NT	NT
				4+	0	0

[1]Grading scale: percent inhibition of $\geq 85\%$ was given a grade of 4+; 70%–85% 3+; 40%–70% 2+; 20%–40% 1+; below 20% 0. GM1 did not inhibit any sera.–[2]NT: not tested.–*Inhibiting on sera with $\geq 1/40$.

murine MAb reactive with both GM3 and GM3-L has been generated (Dohi et al., 1988). Murine MAbs reactive with other ganglioside lactones are also reactive with the parent ganglioside (Bosslet et al., 1989; Dohi et al., 1988; Tai et al., 1988). Serum antibodies induced by immunization of mice with GD3-LI (the lactone ring formed between the carboxyl group of sialic acid and the hydroxyl group of the ganglioside) were shown to react with purified GD3 and GD3 expressing human melanoma cells (Ritter et al., 1990a). With GD3-L/BCG, we were able to induce low-titer antibodies against GD3-L in 4 of 9 patients. However, these antibodies were exclusively IgM, the response was of short duration and no reactivity against GD3 was seen. These results suggested that GD3-L/BCG was a more potent method of immunizing against GD3 than GD3/BCG, but was not potent enough (Ritter et al., 1991).

Several other approaches have been reported to augment the immunogenicity of carbohydrate antigens (Helling et al., 1995; Ragupathi et al., 1998). Covalent attachment of carbohydrate antigens to immunogenic protein carriers as first suggested for haptens and then carbohydrates is the concept that has been pursued most vigorously, especially in vaccines against infectious diseases. Regarding conjugate vaccines against gangliosides, in our initial studies with GD3 vaccines in the mouse, we established the optimal conjugation method, the optimal carrier protein and the necessity for a potent adjuvant (Helling et al., 1994). The optimal conjugation procedure for GD3 was cleavage of the ceramide double bond with ozone, generation of an aldehyde group and coupling to free ε-amino groups of the lysine of protein by reductive amination. We found that KLH was the optimal carrier and QS-21, a homogeneous saponin fraction purified from the bark of Quillaja saponaria, the most effective adjuvant (Helling et al.,

1994). Mice vaccinated with GD3-KLH conjugate plus QS-21 had higher titer IgM antibodies and consistent production of high IgG antibody titers. The superior immunogenicity of the KLH conjugate vaccine plus QS-21 has also been demonstrated in melanoma patients with GM2-KLH (Helling et al., 1995).

Putting together the increased immunogenicity of KLH conjugate plus QS-21 vaccines, the basic ability of the human immune system to produce antibodies recognizing GD3 and the increased immunogenicity of ganglioside GM3-L compared to GM3 in terms of anti-GM3 antibodies, it seemed reasonable to reevaluate the immunogenicity of GD3 and GD3-L using KLH conjugate plus QS-21 vaccines. Others have described clinical trials that occasionally induced antibodies against GD3 in patients (Portoukalian et al., 1991; Ravindranath et al., 1988). We report here an immunization procedure that resulted in the production of IgM and IgG antibodies against GD3 and tumor cells expressing GD3 in the majority of immunized patients. The antibodies produced in response to immunization with GD3-L were specific for GD3-L but also cross-reacted significantly with purified melanoma GD3, GD3 isolated from bovine buttermilk and GD3 on the melanoma cell surface. This is in contrast to the experience of others with MAbs raised against GD3-L which reacted with GD3-L but not with GD3 (Kawashima et al., 1993, 1994). GD3-KLH failed to induce antibody against GD3, suggesting that tolerance to GD3 as a consequence of expression of GD3 on a variety of normal human tissues could be broken by GD3-L but not by GD3. This may be because GD3-L is expressed at lower levels on normal tissues and so is more easily recognized by the immune system, or because GD3-L is a more rigid, less flexible molecule that consequently is a stronger immunogen.

REFERENCES

BOSSLET, K., MENNEL, H.D., RODDEN, F., BAUER, B.L., WAGNER, F., ALTMANNSBERGER, A., SEDLACEK, H.H. and WIEGANDT, H., Monoclonal antibodies against epitopes on ganglioside GD₃ and its lactones. Markers for gliomas and neuroblastomas. Cancer Immunol. Immunother., 29, 171–178 (1989).

DOHI, T., NORES, G. and HAKOMORI, S., An IgG₃ monoclonal antibody established after immunization with GM3 lactone: immunochemical specificity and inhibition of melanoma cell growth in vitro and in vivo. Cancer Res., 48, 5680–5685 (1988).

HAMILTON, W.B., HELLING, F., LLOYD, K.O. and LIVINGSTON, P.O., Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int. J. Cancer, 53, 566–573 (1993).

HELLING, F., SHANG, A., CALVES, M., ZHANG, S., REN, S., YU, R.K., OBTIGEN, H.F. and LIVINGSTON, P.O., GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines. Cancer Res., 54, 197–203 (1994).

HELLING, F., ZHANG, S., SHANG, A., ADLURI, S., CALVES, M., KOGANTY, R., LONGENECKER, B.M., YAO, T.J., OETTGEN, H.F. and LIVINGSTON, P.O., GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res., 55, 2783–2788 (1995).

JURCIC, J.G., SCHEINBERG, D.A. and HOUGHTON, A.N., Monoclonal anti-

body therapy of cancer. In H.M. Pinedo, D.L. Longo and B.A. Chabner (eds.), Cancer chemotherapy and biological response modifiers annual 17, pp. 195–216, Elsevier, Amsterdam (1997).

KAWASHIMA, I., KOTANI, M., OZAWA, H., SUZUKI, M. and TAI, T., Generation of monoclonal antibodies specific for ganglioside lactones: evidence of the expression of lactone on human melanoma cells. Int. J. Cancer, 58, 263–268 (1994).

KAWASHIMA, I., OZAWA, H., KOTANI, M., SUZUKI, M., KAWANO, T., GOBUCHI, M. and TAI, T., Characterization of ganglioside expression in human melanoma cells: immunological and biochemical analysis. J. Biochem., 114, 186–193 (1993).

KENSIL, C.R., PATEL, U., LENNICK, M. and MARCIANI, D., Separation and characterization of saponins with adjuvant activity from Quillaja saponaria, Molina cortex. J. Immunol., 146, 431–437 (1991).

LIVINGSTON, P.O., Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol. Rev., 145, 147–166 (1995).

LIVINGSTON, P.O., ADLURI, S., HELLING, F., YAO, T.J., KENSIL, C.R., NEWMAN, M.J. and MARCIANI, D., Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine, 12, 1275–1280 (1994).

666   RAGUPATHI ET AL.

LIVINGSTON, P.O., WATANABE, T., SHIKU, H., HOUGHTON, A.N., ALBINO, A., TAKAHASHI, T., RESNICK, L.A., MICHITSCH, R. PINSKY, C.M., OETTGEN, H.F. and OLD. L.J., Serological response of melanoma patients receiving melanoma cell vaccines. I. Autologous cultured melanoma cells. *Int. J. Cancer.* 30, 413–422 (1982).

NORES, G.A., DOHI, T., TANIGUCHI, M. and HAKOMORI, S., Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: requirements for tumor-associated antigen and immunogen. *J. Immunol.*, 139, 3171–3176 (1987).

PORTOUKALIAN, J., CARREL, S., DORE, J.-F. and RÜMKE, P., Humoral immune response in disease-free advanced melanoma patients after vaccination with melanoma-associated gangliosides. *Int. J. Cancer.* 49, 893–899 (1991).

PUKEL, C.S., LLOYD, K.O., TRAVASSOS, L.R., DIPPOLD, W.G., OETTGEN, H.F. and OLD, L.J., GD3, A PROMINENT GANGLIOSIDE OF HUMAN MELANOMA. Detection and characterization by a mouse monoclonal antibody. *J. exp. Med.*, 155, 1133–1147 (1982).

RAGUPATHI, G., Carbohydrate antigens as targets for active specific immunotherapy. *Cancer Immunol. Immunother.*, 43, 152–157 (1996).

RAGUPATHI, G., KOGANTY, R.R., QIU, D.X., LLOYD, K.O. and LIVINGSTON, P.O., A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm. *Glycoconjugate J.*, 15, 217–221 (1998).

RAVINDRANATH, M.H., MORTON, D.L. and IRIE, R.F., An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy. *Cancer Res.*, 49, 3891-3897 (1989).

RAVINDRANATH, M.H., PAULSON, J.C. and IRIE, R.F., Human melanoma antigen O-acetylated ganglioside GD3 is recognized by *Cancer antennarius* lectin. *J. biol. Chem.*, 263, 2079–2086 (1988).

RITTER, G., BOOSFELD, E., ADLURI, R., CALVES, M., OETTGEN, H.F., OLD, L.J. and LIVINGSTON, P., Antibody response to immunization with gangli-

oside GD3 and GD3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma. *Int. J. Cancer*, 48. 379–385 (1991).

RITTER, G., BOOSFELD, E., CALVES, M.J., OETTGEN, H.F., OLD, L.J. and LIVINGSTON, P.O., Antibody response to immunization with purified GD3 ganglioside and GD3 derivatives (lactones, amide and gangliosidol) in the mouse. *Immunobiology*, 182, 32–43 (1990a).

RITTER, G., BOOSFELD, E., MARKSTEIN, E., YU, R.K., REN, S.L., STALLCUP, W.B., OETTGEN, H.F., OLD, L.J. and LIVINGSTON, P.O., Biochemical and serological characteristics of natural 9-O-acetyl GD3 from human melanoma and bovine buttermilk and chemically O-acetylated GD3. *Cancer Res.*, 50, 1403–1410 (1990b).

SCHEINBERG, D.A. and CHAPMAN, P.B., Therapeutic applications of monoclonal antibodies for human disease. In: J.R. Birch and E.S. Lennox (eds.), *Monoclonal antibodies. Principles and applications*, pp. 45–105. John Wiley & Sons, New York (1995).

SHIKU, H., TAKAHASHI, T., OETTGEN, H.F. and OLD, L.J., Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new cell surface antigens. *J. exp. Med.*, 144, 873–881 (1976).

SVENNERHOLM, L., Chromatographic separation of human brain gangliosides. *J. Neurochem.*, 10, 613–623 (1963).

TAI, T., KAWASHIMA, I., TADA, N. and IKEGAMI, S., Different reactivities of monoclonal antibodies to ganglioside lactones. *Biochim. biophys. Acta,* 958, 134–138 (1988).

YAMAGUCHI, H., FURUKAWA, K., FORTUNATO, S.R., LIVINGSTON, P.O., LLOYD, K.O., OETTGEN, H.F. and OLD, L.J., Cell-surface antigens of melanoma recognized by human monoclonal antibodies. *Proc. nat. Acad. Sci. (Wash.)*, 84, 2416–2420 (1987).

ZHANG, S., HELLING, P., LLOYD, K.O. and LIVINGSTON, P.O., Increased tumor cell reactivity and complement-dependent cytotoxicity with mixtures of monoclonal antibodies against different gangliosides. *Cancer Immunol. Immunother.*, 40, 88–94 (1995).

Memorial Sloan-Kettering Cancer Center, New York, U.S.A.

Antibody Response to Immunization with Purified GD3 Ganglioside and GD3 Derivatives (Lactones, Amide and Gangliosidol) in the Mouse*

Gerd Ritter**, Erika Boosfeld, Michele J. Calves, Herbert F. Oettgen, Lloyd J. Old, and Philip O. Livingston

Abstract

GD3 is the ganglioside most abundantly expressed on the cell surface of human melanoma, and treatment with a monoclonal antibody recognizing GD3 has induced major responses in a small proportion of patients. However, we have been unable to induce production of GD3 antibodies in melanoma patients by active immunization with GD3-expressing melanoma cells or purified GD3. In this report we describe attempts to increase the immunogenicity of GD3 in the mouse by chemical modification. GD3 lactone I and II, GD3 amide and GD3 gangliosidol were synthesized, and the humoral immune response to these derivatives was compared with the response to unmodified GD3. The GD3 derivatives were more immunogenic than GD3. At a low dose all congeners induced an IgM response, with antibody titers higher than those elicited by low-dose GD3. The gangliosidol and amide derivatives also induced an IgG response. IgM antibodies induced by immunization with GD3 lactone I cross-reacted with purified GD3 and GD3-expressing melanoma cells. Titers of GD3 cross-reactive antibodies were slightly higher than after immunization with GD3 itself at the same low dose. IgM and IgG antibodies induced by the other congeners did not cross-react with GD3.

Introduction

In studies of the humoral immune response to ganglioside vaccines in patients with malignant melanoma, it has been shown that GM2 is consistently immunogenic, that GD2 elicits an antibody response only occa-

Abbreviations: The designations GM3, GM2, GM1, GD3, GD2 and GD1b are used in accordance with the abbreviated ganglioside nomenclature proposed by Svennerholm (33). *ELISA* = enzyme-linked immunosorbent assay; *HPTLC* = high-performance thin-layer chromatography; *ITLC* = immune thin-layer chromatography; *IA* = immune adherence; *PA* = protein A.

with Purified GD3
ctones, Amide and

CALVES, HERBERT F
GSTON

he cell surface of human melanoma.
D3 has induced major responses in a
able to induce production of GD3
ith GD3-expressing melanoma cells
icrease the immunogenicity of GD3
I and II, GD3 amide and GD3
e response to these derivatives was
The GD3 derivatives were more
ced an IgM response, with antibody
ngliosidol and amide derivatives also
unization with GD3 lactone I cross-
a cells. Titers of GD3 cross-reactive
ith GD3 itself at the same low dose.
did not cross-react with GD3.

se to ganglioside vaccines in
en shown that GM2 is con-
ntibody response only occa-

ept. of Immunology, 35031 Abano

GD3, GD2 and GDIb are used in
re proposed by SVENNERHOLM (33).
TLC = high-performance thin-layer
raphy; IA = immune adherence; PA

sionally and that GD3 does not induce production of antibody (1-3). GD3, however, is of interest for vaccine construction because it is the most commonly expressed cell surface ganglioside of human melanomas (4–6) and has been a target for the treatment of melanoma with a monoclonal antibody (7). For this reason, we have attempted to increase the immunogenicity of GD3 by chemical modification, and we have examined the humoral immune response to these GD3 derivatives in the mouse. We report that antibodies raised against GD3 lactone I showed cross-reactivity with GD3 in several assays including reactivity with human melanoma cells expressing GD3, while antibodies induced against GD3 lactone II, GD3 amide and GD3 gangliosidol cross-reacted with GD3 in ELISA but not in the other assays.

Material and Methods

Gangliosides

GM3, GM2, GM1, GD1b and GD3 were provided by Fidia Research Laboratories (Abano Terme, Italy). GD2 was prepared from GD1b by treatment with bovine testis β-galactosidase (8). Gangliosides of the human melanoma cell line SK-MEL-19 were prepared without saponification or peracetylation by published procedures (9, 10).

Ganglioside derivatives

GD3 lactones were prepared by treating calf brain GD3 with glacial acetic acid as described (11). Lactones were separated according to charge by DEAE-Sephadex A-25 chromatography; eluting lactone II in chloroform/methanol/water 30:60:8 v/v and lactone I in 0.05 M NH₄Ac in methanol (12). GD3 amide was obtained by aminolysis of GD3 lactone II (13), followed by treatment with 0.05 M NaOH in methanol for 1 h at 37°C. GD3 gangliosidols were obtained by reduction of GD3 lactone II with sodium borohydride (14). All derivatives were further purified by Sephadex LH-20 chromatography using chloroform/methanol 1:2 v/v as eluent. The structures of GD3 derivatives are shown in Figure 1.


Figure 1. Schematic structures of GD3 derivates used in these studies. For the proposed structures of GD3 lactones refer to reference (11).

Chemicals

HPTLC silica gel plates were obtained from E. Merck (Darmstadt, Germany), nitrocellulose membranes (0.2 μm) from Schleicher and Schnell, Inc. (Keene, NH, USA), Sep-Pak C₁₈ cartridges from Waters Associates (Milford, MA, USA); DEAE-Sephadex A-25, Sephadex G-50 and LH-20, 4-chloro-1-napithol, and p-nitrophenyl phosphate disodium from Sigma Chemical Co. (St. Louis, MO, USA); cyclophosphamide (Cytoxan) from Mead Johnson (Syracuse, NY, USA).

Monoclonal antibodies and enzymes

Rabbit anti-mouse immunoglobulins conjugated with horseradish peroxidase for ITLC were obtained from Dako Corporation (Santa Barbara, CA, USA), rabbit anti-mouse IgM or IgG conjugated with horseradish peroxidase or alkaline phosphatase from Zymed (San Francisco, CA, USA); MAbs R24, C5 and K9 were generated in our laboratory (15). Bovine testis β-galactosidase was obtained from Dr. GEORGE W. JOURDIAN (Michigan State University, Ann Arbor, MI, USA).

High-performance thin-layer chromatography

TLC analysis was performed on HPTLC silica gel plates. Gangliosides and ganglioside derivatives were separated in chloroform/methanol/0.02 % aqueous CaCl₂ 60:35:8 (v/v) solvent, and visualized by staining with orcinol/H₂SO₄ or resorcinol/HCl. Two-dimensional TLC was performed as described (13).

Immunization

Six-week old female BALB/c × C57BL/6 F1 mice were obtained from Jackson Laboratory (Bar Harbor, ME, USA). Mice were injected intraperitoneally with cyclophosphamide (16, 15 mg/kg 3 days before the first immunization. Gangliosides used for immunization were dried in conical tubes and resuspended in distilled water containing the adjuvant *Salmonella minnesota* rough mutant R 595 prepared as described (17). The mixture was lyophilized and emulsified in PBS prior to administration. Mice were injected subcutaneously with a given ganglioside twice, three weeks apart, at a dose of 10 μg glycolipid and 0.5 mg S. minnesota R 595 in 100 μl PBS. Mice were bled from the retro-orbital sinus before and two weeks after the first and second vaccine injection. Serum samples for serological testing were stored at −20 °C.

Dot blot immune stains and enzyme-linked immunosorbent assays

These assays were performed as described previously (10).

Table 1. Immunoreactivity of GD3 derivatives

| Derivative | anti-GD3 mabs | | | | | |
| | K9 | | C5 | | R24 | |
	4 °C	25 °C	4 °C	25 °C	4 °C	25 °C
GD3	++	+++	++	+++	++	+++
GD3 Amide	−	−	−	−	−	−
GD3 Gangliosidol	−	−	−	−	−	−
GD3 Lactone I	−	++	−	++	−¹	++
GD3 Lactone II	−	+	−	+	−	+

* Determined by ITLC; antibody dilution: 20 μg/ml; anti-GD3 antibodies were incubated overnight. Reactivity was grated as follows: +++ strong, ++ moderate, + weak, − not reactive; ¹ minute reactivity.

:k (Darmstadt, Germany); nitrocellu-
ne. (Keene, NH, USA); Sep-Pak (...
DEAE-Sephadex A-25, Sephadex G-
-sphate disodium from Sigma
...oxan) from Mead Johnson

th horseradish peroxidase for ITLC
CA, USA), rabbit anti-mouse IgM or
line phosphatase from Zymed (San
erated in our laboratory (15). Bovine
?, JOURDIAN (Michigan State Univer-

plates. Gangliosides and ganglioside
0.2 % aqueous CaCl₂ 60:35:8 (v/v)
or resorcinol/HCl. Two-dimensional

Obtained from Jackson Laboratory
ly with cyclophosphamide (16) 15
ed for immunization were dried in
the adjuvant *Salmonella minnesota*
was lyophilized and emulsified in
ously with a given ganglioside
S. minnesota R 595 in 100 µl
two weeks after the first and
were stored at −20 °C.

Immune thin-layer chromatography

Immunostaining of gangliosides and ganglioside derivatives with monoclonal antibodies or mouse sera after separation on HPTLC silica gel glass plates was performed as described (18) with minor modifications (19).

Immune adherence and protein A hemadsorption assays

These assays measure antibody mediated rosetting of human RBC (blood group 0) on target cells. Assays were performed as described (20, 21).

Results

Preparation and characteristics of GD3 lactones, amide and gangliosidol

Two major products were obtained by treatment of GD3 with glacial acetic acid. Their TLC-patterns (Fig. 2) corresponded with those of GD3-lactone I and GD3-lactone II as described (11). After mild base treatment, both derivatives co-migrated with the parent GD3. After separation on DEAE-Sephadex A-25 according to charge, lactone I was eluted in the monosialo fraction, whereas lactone II was found in the neutral fraction suggesting that one carboxyl group in lactone I and both carboxyl groups in lactone II were involved in the formation of lactone rings. While no other bands were detected by TLC analysis in the lactone II preparation, the lactone I preparation contained 5–10% GD3. Attempts to remove GD3

R24
4°C   25°C
++   +++
-
-
-+
+
are incubated
weak, − not

— GM3
— GM2
— GM1
— GD1b

1   2   3   4   5   6

Figure 2. TLC analysis of GD3 and GD3 derivatives used in these studies. GD3 lactone I (Lane 1); GD3 lactone II (Lane 2); GD3 amide (Lane 3); GD3 gangliosidol (Lane 4); GD3 (Lane 5); reference gangliosides GM3, GM2, GM1 and GD1b (Lane 6). HPTLC on silica gel plate; running solvent chloroform/methanol/0.22% aqueous CaCl₂ 60:35:8 v/v; staining reagent: orcinol/H₂SO₄.

completely from this preparation failed, because some GD3 was always formed again during the purification steps as a consequence of the labile nature of the GD3 lactone I structure. After aminolysis of GD3 lactone II two major products migrating as double bands were detected by TLC, one migrating slightly faster than GM3, the other migrating between GM3 and GM2. The faster migrating product was converted to the slower migrating product by mild base treatment, and only the latter was used in our studies. In contrast to lactones, the GD3 amide showed uniform motility in two-dimensional TLC analysis, after being kept in a chamber saturated with ammonia between the two runs. The GD3 amide preparation was free of GD3 and other products as determined by TLC. The product obtained after reduction of GD3 lactone II appeared as a double band in TLC, migrating slightly faster than GM3. This gangliosidol preparation contained traces of a product migrating with GD3 lactone II and a double band migrating with GM2 (7 %). When stained with resorcinol reagent only the major double band developed the typical orange-yellowish color that has been described for gangliosidols (22).

Reactivity of GD3 lactones, amide and gangliosidol with anti-GD3 mAbs

Immune reactivity of these GD3 derivatives with murine mAbs R24, C5 and K9 (recognizing GD3) was determined by ITLC. Results are shown in Table 1. None of the GD3 derivatives reacted with anti-GD3 antibodies when incubated at 4 °C overnight. However, both lactones showed some

Table 2. Antibody response of mice after vaccination with GD3 and GD3 derivatives as determined by ELISA[*]

Vaccine	Dose	No. of mice	Target	Titers	
				IgM	IgG
GD3	0.1 μg	5	GD3	–	–
	1 μg	5	GD3	–	–
	10 μg	20	GD3	40 (3)	–
	30 μg	5	GD3	1280 (1), 320 (1), 80 (1), 40 (1)	–
GD3-L I	10 μg	20	GD3-L I	1280 (2), 640 (1), 320 (1), 160 (2), 80 (2), 40 (9)	–
			GD3	640 (1), 160 (2), 80 (7), 40 (7)	–
GD3-L II	10 μg	15	GD3-L II	640 (1), 160 (1), 80 (3)	–
			GD3	40 (5)	–
GD3-A	10 μg	15	GD3-A	1280 (4), 640 (2), 320 (3), 160 (2), 80 (4)	> 1280 (12), 160 (2), 80 (1)
			GD3	640 (2), 160 (2), 80 (3), 40 (2)	40 (1)
GD3-OL	10 μg	15	GD3-OL	1280 (6), 640 (3), 320 (2), 160 (1), 80 (1), 40 (1)	> 1280 (7), 320 (1), 160 (2), 80 (2)
			GD3	80 (1), 40 (1)	–

[*] Reactivity is expressed in reciprocal titers.

d, because some GD3 was always
reps as a consequence of the labile
After aminolysis of GD3 lactone II
: bands were detected by TLC. one
other migrating between GM3 and
: converted to the slower migrating
v the latter was used in our studies.
showed uniform motility in two-
kept in a chamber saturated with
D3 amide preparation was free of
J by TLC. The product obtained
eared as a double band in TLC.
gangliosidol preparation contained
)3 lactone II and a double band
d with resorcinol reagent only the
l orange-yellowish color that has

angliosidol with anti-GD3 mAbs

tives with murine mAbs R24, C5
d by ITLC. Results are shown in
eacted with anti-GD3 antibodies
ver, both lactones showed some

jon with GD3 and GD3 derivatives as

	Titers	
		IgG
		-
		-
80 (1), 40 (1)		-
320 (1).		-
(1)		
(7), 40 (7)		-
(2)		
		-
(2)		-
		> 1280 (12);
		160 (2), 80 (1)
(2)		40 (1)
		> 1280 (7), 320 (1).
		160 (2), 80 (2).

Table 3 Antibody response of mice after vaccination with GD3 and GD3 derivatives as determined by dot blot immune stain

	Vaccine[1]									
	GD3		GD3-L I		GD3-L II		GD3-A		GD3-OL	
Target	Number of reactive mice[2]									
	IgM	IgG	IgM	IgG	IgM	IgG	IgM	IgG	IgM	IgG
GM3	1	-	2	-	-	-	-	-	-	-
GM2	-	-	-	-	-	-	-	-	-	-
GM1	-	-	-	-	-	-	-	-	-	-
GD3	4	-	11	-	3	-	1	-	2	-
GD2	-	-	-	-	-	-	-	-	-	-
GD1b	-	-	-	-	-	-	-	-	1	-
GD3-L I	-	-	11	-	-	-	-	-	1	-
GD3-L II	-	-	-	-	1	-	-	-	-	-
GD3-A	-	-	-	-	-	-	15	15	12	-
GD3-OL	2	-	1	-	-	-	4	-	12	7

[1] Each vaccine contained 10 µg ganglioside.
[2] GD3 and GD3-L I were tested in groups of 20 mice. GD3-L II, GD3-A and GD3-OL in groups of 15 mice.

reactivity when incubated with GD3 antibodies at room temperature overnight. It can not be excluded, however, that this reactivity was due to degradation of GD3 lactone to GD3, which we have shown to occur after overnight incubation at room temperature, but not at 4 °C (23).

Immunogenicity of GD3 and GD3 derivatives in the mouse.

The antibody response of mice after immunization with GD3 or GD3 derivatives was analyzed by ELISA (Table 2), dot blot immune stain (Table 3) and by ITLC (Fig. 3).

GD3: Three of 20 mice immunized with 10 µg GD3 responded with production of low titer IgM antibodies against GD3 as determined by ELISA and dot blot immune stain, but not ITLC. Immunization with 0.1 µg GD3 or 1 µg GD3 did not elicit detectable antibody production, while mice immunized with 30 µg GD3 (a dose previously shown to be immunogenic (24)) responded with production of medium titer IgM antibodies against GD3 as determined by ELISA and dot blot immune stains. No IgG antibodies were detected.

GD3 lactone I: Seventeen of 20 mice immunized with 10 µg GD3 lactone I produced IgM antibodies to GD3 lactone I as detected by ELISA, and eleven of the 20 sera were also reactive by dot blot immune stain. Reactivity of these sera with calf brain GD3 was as follows: ELISA 17/20; dot blot immune stain 11/20. Reactivity with human melanoma-derived GD3 was also detected by ITLC. The sera showed no reactivity with GD3 lactone II or other gangliosides. No IgG antibodies were detected.

Figure 3. ITLC of mouse antisera induced after immunization with GD3 amide (A) and GD3 lactone I (B). Gangliosides extracted from human melanoma cell line SK-MEL 19 (Lane 1); immunogen: GD3 amide (A) or GD3 lactone I (B) (Lane 2); GD3 from calf brain (Lane 3); reference gangliosides GM3, GM2, GM1 and GD1b (Lane 4). HPTLC on silica gel plates; running solvent chloroform/methanol/0.02% aqueous CaCl; 60:35:8 v/v; serum dilution 1:75; staining peroxidase and 4-chloro-1-naphthol.

GD3 lactone II: After immunization with 10 µg GD3 lactone II, five of 15 mice developed low titer IgM antibodies against the immunogen and GD3 by ELISA. None of these sera showed reactivity with GD3 lactone II or GD3 by dot blot immune stain or ITLC. These sera showed no reactivity with GD3 lactone I or other gangliosides. Again, no IgG responses were detected.

GD3 amide: Of the GD3 congeners tested, GD3 amide elicited the strongest antibody response. All 15 mice immunized with 10 µg GD3 amide responded with production of high-titer IgM and IgG antibodies reactive with the immunogen as determined by ELISA and dot blot immune stain. Nine of the IgM sera also reacted with GD3 by ELISA, but only one was reactive with GD3 when tested by dot blot immune stain. ITLC revealed only reactivity with the immunogen. IgM antibodies, but not IgG antibodies, showed reactivity with GD3 gangliosidol but not with other gangliosides as determined by dot blot immune stain.

GD3 gangliosidol: After immunization with 10 µg GD3 gangliosidol IgM antibodies to GD3 gangliosidol were detected by ELISA in 14/15 mice and by dot blot immune stain in 12/15 mice. IgG antibodies in 12/15 and 7/15 mice, respectively. Two of the IgM sera also reacted with GD3 in dot blot immune stain tests. Some sera also showed reactivity with GD3 amide by dot blot immune stain and ITLC.

← GD3-LI

← GD3

3   4

ion with GD3 amide (A) and GD3
ma cell line SK-MEL 19 (Lane 1);
2); GD3 from calf brain (Lane 3);
x 4). HPTLC on silica gel plates;
aCl, 60:35:8 v/v; serum dilution

5n. :

ie:
5 μg GD3 lactone II, five of
against the immunogen and
ctivity with GD3 lactone II
sera showed no reactivity
no IgG responses were

GD3 amide elicited the
with 10 μg GD3 amide
IgG antibodies reactive
blot immune stain.
SA, but only one was
in ITLC revealed
but not IgG anti-
not with other
r.

GD3 gangliosidol
SA in 14/15 mice
es in 12/15 and
GD3 in dot
GD3 amide

No antibodies were induced in mice immunized with R595 alone as tested by ELISA. The results indicate that these GD3 derivatives are significantly more immunogenic in the mouse than unmodified GD3 or any other ganglioside we have tested (24).

Cell surface reactivity of sera from immunized mice with human melanoma cells

Immune sera were tested for cell surface reactivity with melanoma cells expressing high levels of GD3 (SK-MEL-19), moderate GD3 (SK-MEL-28), or low GD3 (SK-MEL-31). Mice immunized with 0.1 or 1 μg GD3 showed no reactivity, mice immunized with 10 μg GD3 some reactivity, and mice immunized with 30 μg GD3 showed good reactivity (Table 4). Of the GD3 derivatives, only GD3 lactone I induced antibodies reactive with human melanoma cells expressing GD3 on their cell surface. Although some sera from mice immunized with other GD3 derivatives were reactive with GD3 in ELISA, they showed no reactivity with melanoma cells.

Discussion

The ganglioside GD3 is abundantly expressed on the cell surface of melanomas and therefore a potential target for immunological attack. Treatment with a monoclonal antibody-recognizing GD3 has induced regression of melanoma metastases in a small proportion of patients (7). Attempts at inducing an antibody response in melanoma patients by active immunization with GD3 have failed, however (25), and this experience has led us to search for ways in which the immunogenicity of GD3 could be

Table 4. Cell surface reactivity of antisera induced by GD3 and GD3 derivatives in the mouse with three human melanoma cell lines[1]

Vaccine	Dose	Target cell line[2]		
		SK-MEL-19	SK-MEL-28	SK-MEL-31
GD3	0.1 μg	0/5	0/5	0/5
	1 μg	0/5	0/5	0/5
	10 μg	3/20	3/20	0/20
	30 μg	4/5	4/5	1/5
GD3-L I	10 μg	7/20	4/20	1/20
GD3-L II	10 μg	1/15	0/15	1/15
GD3-A	10 μg	0/15	0/15	0/15
GD3-OL	10 μg	0/15	0/15	0/15

[1] Reactivity was determined by IA and PA and is expressed in number of reactive mice immunized with a given vaccine. No reactivity by PA was observed.
[2] Level of GD3 expression on cell surface: SK-MEL-19 high; SK-MEL-28 moderate; SK-MEL-31 low.

increased. Several reports indicate that chemical modification may augment the immunogenicity of ganglioside molecules. Ganglioside derivatives that have been previously reported to induce antibody production more readily than the parent molecules include GM1 methylester, GM1 gangliosidol and GM1-N-methylamide (26, 27), GM3 lactone (14, 28) and O-acetylation products of GD3 (10).

We report here that modifications of GD3 resulting in enhanced immunogenicity include the lactone, amide and gangliosidol congeneres. The changes in the molecular structure of GD3 involve loss of charge and altered configuration, hydrophobicity, rigidity and stability. Which of these changes are involved in enhancing immunogenicity is not known. One feature of structurally modified gangliosides is their reduced susceptibility to enzymatic action (26, 29, 30). Higher immunogenicity might result from greater resistance to metabolic degradation, making a lower dose of a GD3 derivative equivalent to an higher dose of GD3. Alternatively, increased immunogenicity might be the consequence of presenting molecular conformations not known to be expressed in mammalian tissue. We have found that the differential expression of individual gangliosides in normal tissues of mice and humans is inversely proportional to their ability to elicit antibody production in these two species (24), suggesting that normal tissue expression rather than chemical structure determines ganglioside immunogenicity.

We were initially impressed by the high-titer antibodies against GD3 detected by ELISA after immunization with some GD3 derivatives (Table 2). However, further testing by dot blot immune stain on nitrocellulose or immune thin-layer chromatography on silica gel plates showed no reactivity with GD3. In our hands, results of dot blot immune stains on nitrocellulose and immune thin-layer chromatography on silica gel plates correlated much better with cell surface reactivity than results of ELISA. Others have also reported that ganglioside antisera show reactivity in ELISA on plastic surfaces but not in other types of tests (31). It appears that epitopes expressed by purified gangliosides in ELISA wells are not necessarily the same epitopes expressed on other artificial matrices or on the cell surface.

In our studies, antisera raised with GD3 amide or GD3 gangliosidol were highly specific for the respective immunogen and showed almost no reactivity with GD3, while antibodies induced by GD3 lactone I (but not lactone II) were equally reactive with GD3 lactone I and with unmodified GD3. Furthermore, these antibodies were reactive with human melanoma cells expressing GD3 on their cell surface, but not reactive with melanoma cells not expressing GD3. Only the GD3 lactone I configuration appeared to be close enough to that of GD3 to induce a crossreactive immune response. Similar observations have been made with GM3. Yu et al. have suggested that the increased hydrophobicity and the more rigid structure of GM3 lactone as compared with native GM3 might favor immunological

ical modification may augment
:s. Ganglioside derivatives that
ibody production more readily
ylester, GM1 gangliosidol and
ne (14, 28) and O-acetylation

GD3 resulting in enhanced
and gangliosidol congeneres.
D3 involve loss of charge and
y and stability. Which of these
genicity is not known. One
is their reduced susceptibility
unogenicity might result from
making a lower dose of a GD3
GD3. Alternatively, increased
f presenting molecular confor-
malian tissue. We have found
gangliosides in normal tissues
nal to their ability to elicit
, suggesting that normal tissue
determines ganglioside im-

titer antibodies against GD3
with some GD3 derivatives
t immune stain on nitrocellu-
n silica gel plates showed no
f dot blot immune stains on
tography on silica gel plates
tivity than results of ELISA.
antisera show reactivity in
es of tests (31). It appears that
ELISA wells are not neces-
tificial matrices or on the cell

r GD3 gangliosidol were
and showed almost no
GD3 lactone I (but not
I and with unmodified
with human melanoma
reactive with melanoma
configuration appeared
crossreactive immune
GM3. Yu et al. have
rigid structure of
immunological

recognition (32), and Nores et al. (14, 28) have shown that an immune
response against GM3 could be induced with GM3 lactone but not with
unmodified GM3.

Our findings suggest that chemical modifications of melanoma gan-
gliosides may increase their immunogenicity and that some chemically
modified melanoma gangliosides can be used to construct immunogenic
vaccines for immunization of patients with melanoma. We need to keep in
mind, however, that the human immune system may not recognize the
same epitopes that are recognized in the mouse. Studies investigating the
immune response of patients with melanoma to immunization with GD3
derivatives are now underway.

References

1. LIVINGSTON, P. O., E. J. NATOLI, M. JONESCALVES, E. STOCKERT, H. F. OETTGEN, and L. J. OLD. 1987. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc. Natl. Acad. Sci. USA. 84: 2911.
2. TAI, T., L. D. CAHAN, T. TSUCHIDA, R. E. SAXTON, R. F. IRIE, and D. L. MORTON. 1985. Immunogenicity of melanoma-associated gangliosides in cancer patients. Int. J. Cancer 35: 607.
3. LIVINGSTON, P. O., E. KAELIN, C. M. PINSKY, H. F. OETTGEN, and L. J. OLD. 1985. IV. Serological response in stage II melanoma patients receiving allogeneic melanoma cell vaccines. Cancer 56: 2194.
4. TSUCHIDA, T., R. H. RAVINDRANATH, R. E. SAXTON, and R. F. IRIE. 1987. Gangliosides of human melanoma: altered expression in vivo and in vitro. Cancer Res. 47: 1278.
5. WELT, S., E. A. CARSWELL, C.-W. VOGEL, H. F. OETTGEN, and L. J. OLD. 1987. Immune and nonimmune effector functions of IgG3 mouse mAb R24 detecting the disialogan-glioside GD3 on the surface of melanoma cells. Clin. Immunol. Immunopath. 45: 214.
6. CARUBIA, J. M., R. K. YU, L. J. MACALA, J. M. KIRKWOOD, and J. M. VARGA. 1984. Gangliosides of normal and neoplastic melanocytes. Biochem. Biophys. Res. Comm. 120: 500.
7. HOUGHTON, A. N., M. MINTZER, C. CORDON-CARDO, S. WELT, B. FLIEGEL, S. VADHAN, E. CARSWELL, M. R. MELAMED, H. F. OETTGEN, and L. J. OLD. 1985. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc. Natl. Acad. Sci. USA. 82: 1242.
8. CAHAN, L. D., R. F. IRIE, R. SINGH, A. CASSIDENTI, and J. C. PAULSON. 1982. Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2. Proc. Natl. Acad. Sci. USA. 79: 7629.
9. MOMOI, T., and H. WIEGANDT. 1980. Separation and micro-detection of oligosaccharides of GSL by HP-cellulose thin-layer chromatography-autoradiography. Hoppe-Seyler's Z. Physiol. Chem. 361: 1209.
10. RITTER, G., E. BOOSFELD, E. MARKSTEIN, R. K. YU, S. REN, W. B. STALLCUP, H. F. OETTGEN, L. J. OLD, and P. O. LIVINGSTON. 1990. Biochemical and serological charac-teristics of natural 9-O-acetyl GD3 from human melanoma, bovine buttermilk and chemically O-acetylated GD3. Cancer Res. 50: 1403.
11. ANDO, S., R. K. YU, J. N. SCARSDALE, S. KUSUNOKI, and J. H. PRESTEGARD. 1989. High resolution proton NMR studies of gangliosides. Structure of two types of GD3 lactones and their reactivity with mAb R24. J. Biol. Chem. 264: 3478.
12. IWAMORI, M., and Y. NAGAI. 1978. A new approach to the resolution of individual gangliosides by ganglioside mapping. Biochim. Biophys. Acta 528: 257.

13. SONNINO, S., R. GHIDONI, V. CHIGORNO, M. MASSERINI, and G. TETTAMANTI. 1983. Recognition by two-dimensional TLC and densitometric quantification of alkali-labile gangliosides from the brain of different animals. Anal. Biochem. 128: 104.

14. NORES, G. A., T. DOHI, M. TANIGUCHI, and S. I. HAKOMORI. 1987. Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: J. Immunol. 139: 3171.

15. DIPPOLD, W. G., K. O. LLOYD, L. T. LI, H. IKEDA, H. F. OETTGEN, and L. J. OLD. 1980. Cell surface antigens of human malignant melanoma: definition of six antigenic systems with monoclonal antibodies. Proc. Natl. Acad. Sci. USA. 77: 6114.

16. LIVINGSTON, P. O., A. B. DELEO, M. JONES, and H. F. OETTGEN. 1983. Comparism of approaches for augmenting the serolog. response to the individually spec. methylcholan-threne-induced sarcoma-Meth A. J. Immunol. 131: 2601.

17. LIVINGSTON, P. O., M. JONESCALVES, and E. J. NATOLI. 1987. Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice. Purified GM2 is superior to whole cells. J. Immunol. 138: 1524.

18. MAGNANI, J. L., D. F. SMITH, and V. GINSBURG. 1980. Detection of gangliosides that bind cholera toxin: direct binding of 125I-labeled toxin to thin-layer chromatograms. Anal. Biochem. 109: 399.

19. RITTER, G., W. KRAUSE, R. GEYER, S. STIRM, and H. WIEGANDT. 1987. Glycosphingolipid composition of human semen. Arch. Biochem. Biophys. 257: 370.

20. SHIKU, H., T. TAKAHASHI, H. F. OETTGEN, and L. J. OLD. 1976. Cell surface antigens of human malignant melanoma. J. Exp. Med. 144: 873.

21. PFREUNDSCHUH, M., H. SHIKU, T. TAKAHASHI, R. UEDA, J. RANSOHOFF, H. F. OETTGEN, and L. J. OLD. 1978. Serological analysis of cell surface antigens of malignant human brain tumors. Proc. Natl. Acad. Sci. USA. 75: 5122.

22. MACDONALD, D. L., L. M. PATT, and S. I. HAKOMORI. 1980. Notes on improved procedures for the chemical modification and degradation of glycosphingolipids. J. Lipid Res. 21: 642.

23. RITTER, G., P. O. LIVINGSTON, E. BOOSFELD, H. WIEGANDT, R. K. YU, H. F. OETTGEN, and L. J. OLD. 1989. Development of melanoma vaccines: Gangliosides as immunogens. In: Gangliosides and cancer. OETTGEN, H. F. (ed.) VCH Verlagsgesellschaft Weinheim West Germany. 301 pp.

24. LIVINGSTON, P. O., G. RITTER, and M. J. CALVES. 1989. Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse. Cancer Immunol. Immunother. 29: 179.

25. LIVINGSTON, P. O., G. RITTER, H. F. OETTGEN, and L. J. OLD. 1989. Immunization of melanoma patients with purified gangliosides. In: Gangliosides and cancer. OETTGEN, H. F. (ed.) VCH Verlagsgesellschaft Weinheim West Germany. 293 pp.

26. NAKAMURA, K., and S. HANDA. 1986. Biochemical properties of N-methyl-amides of sialic acids in gangliosides. J. Biochem. 99: 219.

27. HANDA, S., and K. NAKAMURA. 1984. Modification of sialic acid carboxyl group of gangliosides. J. Biochem. 95: 1323.

28. DOHI, T., G. NORES, and S. I. HAKOMORI. 1988. An IgG3 mAb established after immunization with GM3 lactone: Immunochemical specificity and inhibition of melanoma cell growth. Cancer Res. 48: 5680.

29. KLEIN, D., G. POHLENTZ, U. HINRICHS, and K. SANDHOFF. 1987. Metabolism of ganglioside-amides in cultured human fibroblasts. Biol. Chem. Hoppe' Seyler 368: 1496.

30. LI, S. C., S. SERIZAWA, Y. T. LI, K. NAKAMURA, and S. HANDA. 1984. Effect of modification of sialic acid on enzymatic hydrolysis of gangliosides GM1 and GM2. J. Biol. Chem. 259: 5409.

31. GILLARD, B. K., J. W. THOMAS, L. J. NELL, and D. M. MARCUS. 1989. Antibodies against ganglioside GT3 in the sera of patients with type 1 diabetes mellitus. J. Immunol. 142: 3826.

32. YU, R. K., T. A. W. KOERNER, S. ANDO, H. C. YOHE, and J. H. PRESTEGARD. 1985. High-

...ann, and G. Tettamanti. 1983. ...ric quantification of alkali-labile ...iochem. 128: 104.

...ou. 1987. Density-dependent ...antibody, and GM3 lactone as

...Oettgen and L. J. Old. 1980. ...ion of six antigenic systems ...6114.

...tgen. 1983. Comparism of ...idually spec. methylcholan-
...

...Approaches to augmenting ...GM2 is superior to whole

...of gangliosides that bind ...chromatograms. Anal.

...1987. Glycosphingolipid

...cell surface antigens of

...off, H. F. Oettgen, ...malignant human brain

...Notes on improved ...phingolipids. J. Lipid

...Yu, H. F. Oettgen, ...des as immunogens. ...ellschaft weinheim

...body response after ...GD3 in the mouse.

...Immunization of ...OETTGEN, H.

...yl-amides of

...boxyl group of

...ablished after ...hibition of

...olism of gan- ...68: 1496.

...Effect of ...M2 J. Biol.

...against ...ol. 142:

...High-

resolution proton NMR studies of gangliosides. III. Elucidation of the structure of GM3 lactone. J. Biochem. 98: 1367.

33. Svennerholm, L. 1963. Chromatographic separation of human brain gangliosides. J. Neurochem. 10: 613.

Dr. Gerd Ritter, Fidia Research Laboratories, Department of Immunology, 35031 Abano Terme, Via Ponte della Fabbrica 3 A, Italy